| 拉米夫定治疗慢性乙型肝炎患者3年疗效观察 |
| |
| 引用本文： | 李建国,柴艳云,刘密霞,秦惠清,王先英.拉米夫定治疗慢性乙型肝炎患者3年疗效观察[J].实用肝脏病杂志,2010,13(2):97-99. |
| |
| 作者姓名： | 李建国 柴艳云 刘密霞 秦惠清 王先英 |
| |
| 作者单位： | 1. 山西省晋城煤业集团总医院感染病科,048006
2. 山西省晋城煤业集团总医院护理部,048006 |
| |
| 摘 要： | 目的初步探讨LAM长期治疗HBeAg阳性和HBeAg阴性的两组慢性乙型肝炎(CHB)患者生化学、病毒学指标的变化及临床转归的差异。方法对63例诊断为CHB的患者均给予拉米夫定100mg,每日一次,进行3年的随访观察,动态检测患者的HBV血清标志物,HBV DNA,ALT、AFP、YMDD变异、B超等指标。结果拉米夫定治疗HBeAg阳性和HBeAg阴性的CHB患者3年时,HBeAg阳性组ALT复常率、HBV DNA阴转率、肝细胞癌发生率及HBsAg阴转率分别为64.7%、64.7%、0%、0%;HBeAg阴性组ALT复常率、HBV DNA阴转率、肝细胞癌发生率及HBsAg阴转率分别为70.4%、77.8%、0%、0%。两组间ALT复常率、HBV DNA阴转率、肝细胞癌发生率及HBsAg阴转率两组差异均无统计学意义(P0.05);HBeAg阳性组YMDD变异率(43.3%)显著高于HBeAg阴性组(18.2%),x2=4.720,P0.05;HBeAg阴性组肝硬化患者(37.0%)显著高于HBeAg阳性组(5.9%),x2=3.866,P0.05。结论拉米夫定治疗HBeAg阳性CHB患者较HBeAg阴性患者更容易发生YMDD变异,HBeAg阴性CHB患者较HBeAg阳性患者更易发生肝硬化。
|
| 关 键 词： | 慢性乙型肝炎 HBeAg 拉米夫定 YMDD变异 肝硬化 |
Clinical observation of lamivudine in patients with chronic hepatitis B for three years |
| |
| LI Jianguo,CHAI Yanyun,LIU Mixia,et al..Clinical observation of lamivudine in patients with chronic hepatitis B for three years[J].Journal of Clinical Hepatology,2010,13(2):97-99. |
| |
| Authors: | LI Jianguo CHAI Yanyun LIU Mixia |
| |
| Institution: | LI Jianguo,CHAI Yanyun,LIU Mixia,et al.General Hospital of Jincheng Coal Group,Jincheng 048006,China |
| |
| Abstract: | Objective To evaluate the diversity of biochemical virological indicator and the different clinical prognosis between HBeAg-positive and HBeAg-negative chronic hepatitis B group(CHB) patients with the long term therapy of lamivudine.Methods Sixty-three patients with chronic hepatitis B were treated with lamivudine,100mg/d and observed for three years.The serum HBV markers,HBV DNA,ALT,AFP and other biochemical indicators were detected.Results In the HBeAg-positive therapy group,the ratio of ALT normalization... |
| |
| Keywords: | Chronic hepatitis B Hepatitis B e antigens Lamivudine YMDD mutation Liver Cirrhosis |
| 本文献已被 CNKI 维普 万方数据 等数据库收录！ |
|
